VivoSeq
Cardiovascular

Acute Coronary Syndrome

152

Pipeline Programs↗

28

Active Trials↗

55

Companies Involved↗

Acute Coronary Syndrome is a highly competitive landscape with 152 programs across 55 companies. The most active players are Hope Pharmaceuticals, Astellas, Eisai. 74 therapies are approved with 26 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

77/100

Pipeline Velocity

30/100

Mech. Concentration

11/100

Completion Rate

87/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

Hope Pharmaceuticals

1 program

Phase 1Astellas logo

Astellas

2 programs

Phase 2Eisai logo

Eisai

1 program

Phase 2V

Viron Therapeutics Inc

1 program

Phase 2C

Cerenis Therapeutics, SA

1 program

Phase 2R

Regado Biosciences, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical19

Isosorbide Dinitrate

AstraZeneca

Brilinta

AstraZeneca

Ezetimibe

Organon and Co

Influenza Vaccine

Novartis

Nicotine

Pfizer

Phase 16

Enoxaparin Sodium

Sanofi

Citalopram

AbbVie

Sodium Thiosulfate

Hope Pharmaceuticals

Everolimus

Novartis

Lovenox

University of Monastir

Phase 227

Valsartan

Novartis

Pentoxifylline

Validus Pharmaceuticals

Aliskiren

Tibotec Pharmaceuticals, Ireland

Serine Proteinase-1 (serp-1)

Viron Therapeutics Inc

Pravastatin

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 326

Ranolazine

Menarini International Operations Luxembourg SA

Influenza Virus Vaccine

Sanofi

Lixisenatide

Sanofi

Metformin

EMD Serono

Varenicline

Prism Pharmaceuticals

Approved74

Fondaparinux

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Rivaroxaban

Wim Janssens

Statin

Bristol-Myers Squibb

Bivalirudin

Baxter Healthcare Corporation

Ticagrelor

AstraZeneca

Analysis

Modality Breakdown

92%

Small molecule

163 of 178 classified programs — the dominant modality here.

8%ALL OTHERSMonoclonal antibody53%Vaccine42%Protein / enzyme32%Peptide21%RNA therapy1<1%

Small molecule leads; the ring shows all 178 classified programs, each share of the total. Modality classified for 99% of 184 pipeline programs.

Analysis

Trial Status

235

clinical trials

Completed141 · 60%
Unknown status44 · 19%
Recruiting19 · 8%
Terminated16 · 7%
Not yet recruiting7 · 3%
Withdrawn4 · 2%
Other4 · 2%

Clinical Trials

Trial Activity

235 trials

Coenzyme Q10 Role in Prevention of Contrast Induced Nephropathy in Acute Coronary Syndrome Patients.
Recruiting·—·Phase 4·NCT06429345·250 enrolled
IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome
Recruiting·SShanghai Zhongshan Hospital·Phase 4·NCT06451198·2,846 enrolled
Evaluation of the Effectiveness of Platelet-based and Microvesicle-based Assays to Predict Thrombotic and Bleeding Risk in Chronic Kidney Disease Patients With Acute Coronary Syndrome
Recruiting·AAssistance Publique Hopitaux De Marseille·N/A·NCT06026436·850 enrolled
Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome
Recruiting·FFundación para la Investigación del Hospital Clínico de Valencia·Phase 4·NCT07476859·538 enrolled
A Clinical Study of MT1002 in Subjects With Acute Coronary Syndrome Undergoing PCI
Recruiting·SShaanxi Micot Pharmaceutical Technology Co., Ltd.·Phase 2·NCT06533358·20 enrolled
Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome
Recruiting·KKing Edward Medical University·Phase 4·NCT06765265·152 enrolled
Effect of Colchicine on Coronary Reperfusion in Patients With Acute Coronary Syndrome
Recruiting·PPontificia Universidad Catolica de Chile·Phase 2·NCT05472337·50 enrolled
Comparison of Short Versus 12 Months Prasugrel Plus Aspirin in Patients with Acute Coronary Syndromes Treated with Percutaneous Coronary Intervention and Everolimus-eluting Stents
Recruiting·OOdense University Hospital·Phase 4·NCT06718179·3,150 enrolled
Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)
Recruiting·—·N/A·NCT06738758·6,000 enrolled
Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention
Recruiting·FFu Wai Hospital, Beijing, China·Phase 4·NCT04240834·1,220 enrolled
Influenza Vaccination After Acute Coronary Syndrome
Recruiting·TTongji Hospital·N/A·NCT07259252·6,620 enrolled
Treatment of ACuTe Coronary Syndromes With Low-dose colchICine
Recruiting·—·N/A·NCT06215989·6,574 enrolled
Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
Recruiting·JJiangsu vcare pharmaceutical technology co., LTD·Phase 3·NCT06577519·1,000 enrolled
A sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients
Recruiting·SShanghai Tong Ren Hospital·Phase 4·NCT04307511·40 enrolled
Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary Syndromes
Recruiting·UUniversity of Sao Paulo·Phase 2/3·NCT06286878·80 enrolled
Page 1 of 16

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)